Related Experiment Video

Updated: Oct 24, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer

J Tang1, H Pan2, W Wang3

  • 1Department of Gynecology and Obstetrics, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou Normal University, Huzhou, 313003, People's Republic of China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 13, 2021
PubMed
Abstract

Insights

MicroRNA-143-3p and microRNA-495-3p target cyclin-dependent kinase 1 (CDK1) in cervical cancer. Their co-targeting inhibits cervical cancer cell viability and tumorigenicity, suggesting a therapeutic role.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cyclin-dependent kinase 1 (CDK1) is implicated in cervical cancer progression via cell cycle regulation.
  • MicroRNAs (miRNAs) are key regulators of gene expression and can act as tumor suppressors or oncogenes.

Purpose of the Study:

  • To elucidate the role of CDK1 in cervical cancer.
  • To investigate the regulatory function of upstream microRNA (miR)-143-3p and miR-495-3p on CDK1 in cervical cancer.

Main Methods:

  • Quantitative reverse transcription PCR (RT-qPCR) to assess miRNA and CDK1 expression.
  • Cell counting kit-8 (CCK-8) and flow cytometry for cell viability and apoptosis assays.
  • Dual luciferase reporter assay to confirm direct targeting.
  • In vivo xenograft mouse model to evaluate tumorigenicity.

Main Results:

  • CDK1 is a common target of miR-143-3p and miR-495-3p.
  • CDK1 was overexpressed, while miR-143-3p and miR-495-3p were downregulated in cervical cancer tissues and cells.
  • Overexpression of miR-143-3p or miR-495-3p, or CDK1 silencing, inhibited cell viability and promoted apoptosis.
  • In vivo, miR-143-3p/miR-495-3p overexpression suppressed tumor growth, an effect counteracted by CDK1 overexpression.

Conclusions:

  • miR-143-3p and miR-495-3p act as tumor suppressors in cervical cancer by co-targeting CDK1.
  • This miRNA-CDK1 axis plays a crucial role in inhibiting cervical cancer occurrence and development.
Keywords:
ApoptosisCDK1Cervical cancerProliferationmiR-143-3pmiR-495-3p

More Related Videos

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.6K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K